-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AQSOGWkzAXi+vWBFUWPXsS5s1+ToWsY0axtcqVP153T4TCnpwvn55Hds/Vkg9fXB x8+Fdso0LBwCnHYGNz8GgA== 0000891836-05-000130.txt : 20050214 0000891836-05-000130.hdr.sgml : 20050214 20050214144114 ACCESSION NUMBER: 0000891836-05-000130 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20041231 FILED AS OF DATE: 20050214 DATE AS OF CHANGE: 20050214 EFFECTIVENESS DATE: 20050214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 05608039 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 sc0057.txt HOLDINGS REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: December 31, 2004 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. February 14, 2005 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 43 ----------- Form 13F Information Table Entry Value: 259,140 ----------- (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VOTING AUTHORITY -------------------- TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Adolor Corp. COM 00724X102 4,383 441,837 SH SOLE 441,837 Alexion Pharmaceuticals Inc. COM 015351109 9,322 369,938 SH SOLE 369,938 Alkermes Inc. COM 01642T108 2,227 158,059 SH SOLE 158,059 Amgen Inc. COM 031162100 6,412 99,954 SH SOLE 99,954 Amylin Pharmaceuticals Inc. COM 032346108 19,692 842,982 SH SOLE 842,982 Array Biopharma Inc. COM 04269X105 2,127 223,474 SH SOLE 223,474 Atherogenics Inc. COM 047439104 1,314 55,789 SH SOLE 55,789 Barrier Therapeutics Inc. COM 06850R108 7,794 469,528 SH SOLE 469,528 Biocryst Pharmaceuticals COM 09058V103 505 87,451 SH SOLE 87,451 Cell Therapeutics Inc. COM 150934107 759 93,297 SH SOLE 93,297 Critical Therapeutics Inc. COM 22674T105 239 29,854 SH SOLE 29,854 Cytokinetics Inc. COM 23282W100 1,213 118,300 SH SOLE 118,300 Dynavax Technologies Corp. COM 268158102 473 59,100 SH SOLE 59,100 GTX Inc. Del COM 40052B108 4,258 315,653 SH SOLE 315,653 Incyte Corp. COM 45337C102 33,108 3,314,070 SH SOLE 3,314,070 Inhibitex Inc. COM 45719T103 5,449 677,730 SH SOLE 677,730 Insmed Inc. COM 457669208 108 48,900 SH SOLE 48,900 Intermune Inc. COM 45884X103 3,241 244,414 SH SOLE 244,414 Intrabiotics Pharmaceuticals COM 46116T506 3,833 939,561 SH SOLE 939,561 Ligand Pharmaceuticals Inc. CLB 53220K207 1,610 138,357 SH SOLE 138,357 Metabasis Therapeutics Inc. COM 59101M105 2,411 332,502 SH SOLE 332,502 Myogen Inc. COM 62856E104 10,021 1,241,788 SH SOLE 1,241,788 Myriad Genetics Inc. COM 62855J104 853 37,888 SH SOLE 37,888 Nastech Pharmaceutical Inc. COM 631728409 2,547 210,456 SH SOLE 210,456 Neurogen Corp. COM 64124E106 49,851 5,325,999 SH SOLE 5,325,999 Nitromed Inc. COM 654798503 2,665 100,000 SH SOLE 100,000 Onyx Pharmaceuticals Inc. COM 683399109 2,635 81,354 SH SOLE 81,354 Pharmacyclics Inc. COM 716933106 612 58,420 SH SOLE 58,420 Pozen Inc. COM 73941U102 570 78,400 SH SOLE 78,400 Praecis Pharmaceuticals Inc. COM 739421105 95 50,100 SH SOLE 50,100 QLT Inc. COM 746927102 3,304 205,486 SH SOLE 205,486 Renovis Inc. COM 759885106 187 12,996 SH SOLE 12,996 Seattle Genetics Inc. COM 812578102 1,503 230,166 SH SOLE 230,166 Senomyx Inc. COM 81724Q107 7,006 846,104 SH SOLE 846,104 Sequenom Inc. COM 817337108 70 48,881 SH SOLE 48,881 Transkaryotic Therapies Inc. COM 893735100 2,360 92,961 SH SOLE 92,961 Trimeris Inc. COM 896263100 51,046 3,602,369 SH SOLE 3,602,369 Vicuron Pharmaceuticals Inc. COM 926471103 216 12,400 SH SOLE 12,400 Virologic Inc. COM 92823R201 1,262 452,307 SH SOLE 452,307 Incyte Corp Notes 5.5% 2/01/2007 CONV BONDS 45337CAC6 2,500 2,500,000 PRN SOLE 2,500,000 Incyte Corp Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 4,520 4,000,000 PRN SOLE 4,000,000 Regeneron Conv Notes 5.5% 10/17/08 (144A) CONV BONDS 75886FAA5 11,922 12,322,000 PRN SOLE 12,322,000 Regeneron Conv Notes 5.5% 10/17/08 CONV BONDS 75886FAB3 4,838 5,000,000 PRN SOLE 5,000,000
-----END PRIVACY-ENHANCED MESSAGE-----